Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis (MANGO)

Professor Mikkel Østergaard

Status: Completed

Conditions: Axial Spondyloarthritis

Treatments: Drug: Treatment

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02011386

MANGO

Details and patient eligibility

About

The study investigates different criteria for remission based on MRI and circulating biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates factors that affect disease activity, function and participation by use of different questionnaires.

Enrollment: 53 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Axial spondyloarthritis according to the Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axial spondyloarthritis
• Sacroiliitis on conventional X-rays or Magnetic Resonance Imaging (MRI).
• Disease activity assessed by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >40 mm despite treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAID).
• Clinical indication for tumor necrosis factor (TNF) inhibitor treatment by the treating physician.

Exclusion criteria

• No contraindications for TNF inhibitor
• No contraindications for MRI
• No contraindications in participation in a study

Trial design

53 participants in 1 patient group

Treatment

Description:

Treatment: Injection Golimumab 50 mg every month on the same date

Treatment:

Drug: Treatment